Integrating Cellular Metabolism into a Multiscale Whole-Body Model
暂无分享,去创建一个
Steffen Borchers | Rolf Findeisen | Markus Krauss | Jörg Lippert | Stephan Schaller | Lars Kuepfer | R. Findeisen | L. Kuepfer | S. Borchers | J. Lippert | Markus Krauss | S. Schaller
[1] Monica L. Mo,et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.
[2] Francis H. McCrudden. Uric Acid: The Chemistry, Physiology and Pathology of Uric Acid and the Physiologically Important Purin Bodies, with a Discussion of the Metabolism in Gout , 2010 .
[3] N. Vermeulen,et al. Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention. , 1992, Drug metabolism reviews.
[4] Malcolm Rowland,et al. Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.
[5] Markus J. Herrgård,et al. Integrating high-throughput and computational data elucidates bacterial networks , 2004, Nature.
[6] Jörg Lippert,et al. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools , 2005, Expert opinion on drug metabolism & toxicology.
[7] M. Wenk,et al. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities , 1999, European Journal of Clinical Pharmacology.
[8] U. Sauer,et al. Large-scale 13C-flux analysis reveals mechanistic principles of metabolic network robustness to null mutations in yeast , 2005, Genome Biology.
[9] Wolfgang Weiss,et al. A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..
[10] Stefan Willmann,et al. Pharmacogenomics of Codeine, Morphine, and Morphine-6-Glucuronide , 2012, Molecular Diagnosis & Therapy.
[11] Luke Hunter,et al. Interpreting Metabolomic Profiles using Unbiased Pathway Models , 2010, PLoS Comput. Biol..
[12] Kathryn A. Phillips,et al. Diagnostics and biomarker development: priming the pipeline , 2006, Nature Reviews Drug Discovery.
[13] Jonathan C. Cohen,et al. Adult-onset ornithine transcarbamylase (OTC) deficiency unmasked by the Atkins' diet. , 2010, Journal of hepatology.
[14] L. Kuepfer,et al. Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling , 2012, Drug Metabolism and Disposition.
[15] S. Schuster,et al. Analysis of structural robustness of metabolic networks. , 2004, Systems biology.
[16] Carmen G. Moles,et al. Parameter estimation in biochemical pathways: a comparison of global optimization methods. , 2003, Genome research.
[17] William M. Lee,et al. Acetaminophen‐induced acute liver failure: Results of a United States multicenter, prospective study , 2005, Hepatology.
[18] G Levy,et al. Renal clearance and serum protein binding of acetaminophen and its major conjugates in humans. , 1984, Journal of pharmaceutical sciences.
[19] Erwin P. Gianchandani,et al. Dynamic Analysis of Integrated Signaling, Metabolic, and Regulatory Networks , 2008, PLoS Comput. Biol..
[20] Frederick Van Lente,et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. , 2003, The American journal of medicine.
[21] J. Doyle,et al. Bow Ties, Metabolism and Disease , 2022 .
[22] Matthias Hermes,et al. Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration , 2010, Proceedings of the National Academy of Sciences.
[23] O. Demin,et al. The Edinburgh human metabolic network reconstruction and its functional analysis , 2007, Molecular systems biology.
[24] H. J. Greenberg,et al. Monte Carlo sampling can be used to determine the size and shape of the steady-state flux space. , 2004, Journal of theoretical biology.
[25] F. Doyle,et al. Dynamic flux balance analysis of diauxic growth in Escherichia coli. , 2002, Biophysical journal.
[26] Walter Schmitt,et al. Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[27] J. Wahren,et al. Ammonia metabolism during exercise in man. , 1985, Clinical physiology.
[28] E. Ruppin,et al. Predicting metabolic biomarkers of human inborn errors of metabolism , 2009, Molecular systems biology.
[29] F. Theil,et al. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. , 2001, Journal of pharmaceutical sciences.
[30] Walter Schmitt,et al. PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model , 2003 .
[31] Markus J. Herrgård,et al. Network-based prediction of human tissue-specific metabolism , 2008, Nature Biotechnology.
[32] Aarash Bordbar,et al. A multi-tissue type genome-scale metabolic network for analysis of whole-body systems physiology , 2011, BMC Systems Biology.
[33] B. Palsson,et al. Genome-scale models of microbial cells: evaluating the consequences of constraints , 2004, Nature Reviews Microbiology.
[34] L F Prescott,et al. Kinetics and metabolism of paracetamol and phenacetin. , 1980, British journal of clinical pharmacology.
[35] Lei Shi,et al. Synthesis of Resveratrol Analogues, and Evaluation of Their Cytotoxic and Xanthine Oxidase Inhibitory Activities , 2008, Chemistry & biodiversity.
[36] K. Heard,et al. Acetylcysteine for acetaminophen poisoning. , 2008, The New England journal of medicine.
[37] F. Larsen,et al. Persistent Arterial Hyperammonemia Increases the Concentration of Glutamine and Alanine in the Brain and Correlates with Intracranial Pressure in Patients with Fulminant Hepatic Failure , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[38] U. Sauer,et al. Systematic evaluation of objective functions for predicting intracellular fluxes in Escherichia coli , 2007, Molecular systems biology.
[39] Roger Harrison,et al. Structure and function of xanthine oxidoreductase: where are we now? , 2002, Free radical biology & medicine.
[40] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[41] Stefan Willmann,et al. Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. , 2012, Molecular diagnosis & therapy.
[42] L. Kuepfer. Towards whole-body systems physiology , 2010, Molecular systems biology.
[43] N E Maestri,et al. Plasma glutamine concentration: a guide in the management of urea cycle disorders. , 1992, The Journal of pediatrics.
[44] J. Selbig,et al. Parallel analysis of transcript and metabolic profiles: a new approach in systems biology , 2003, EMBO reports.
[45] Jason A. Papin,et al. Genome-scale microbial in silico models: the constraints-based approach. , 2003, Trends in biotechnology.
[46] B. Ross,et al. Severity of Hyperammonemic Encephalopathy Correlates with Brain Ammonia Level and Saturation of Glutamine Synthetase In Vivo , 1996, Journal of neurochemistry.
[47] C. Gille,et al. HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology , 2010, Molecular systems biology.
[48] R. Oberbauer,et al. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. , 1999, British journal of clinical pharmacology.
[49] Nicola Brunetti-Pierri,et al. Inborn errors of metabolism: the flux from Mendelian to complex diseases , 2006, Nature Reviews Genetics.
[50] Lars Kuepfer,et al. Multiscale mechanistic modeling in pharmaceutical research and development. , 2012, Advances in experimental medicine and biology.
[51] Alan H. Lockwood,et al. Blood Ammonia Levels and Hepatic Encephalopathy , 2004, Metabolic Brain Disease.
[52] W. Schmitt,et al. A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats , 2003, Pharmaceutical Research.
[53] Walter Schmitt,et al. Physiology-based pharmacokinetic modeling: ready to be used. , 2004, Drug discovery today. Technologies.
[54] Laura P James,et al. Acetaminophen‐Induced Hepatotoxicity: Role of Metabolic Activation, Reactive Oxygen/Nitrogen Species, and Mitochondrial Permeability Transition , 2004, Drug metabolism reviews.
[55] Tatsuo Hosoya,et al. [Hyperuricemia and gout]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.
[56] Stefan Willmann,et al. Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[57] Nan Xiao,et al. Integrating metabolic, transcriptional regulatory and signal transduction models in Escherichia coli , 2008, Bioinform..
[58] Simeone Marino,et al. Understanding the Immune Response in Tuberculosis Using Different Mathematical Models and Biological Scales , 2005, Multiscale Model. Simul..
[59] Yoshiaki Matsumoto,et al. Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain. , 2007, Biological & pharmaceutical bulletin.
[60] H Derendorf,et al. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[61] Ivan Nestorov,et al. Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.
[62] Kay Brune,et al. Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in man , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[63] M. Rowland,et al. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.
[64] R K Jain,et al. Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.
[65] David S. Wishart,et al. HMDB: a knowledgebase for the human metabolome , 2008, Nucleic Acids Res..
[66] M. Rowland,et al. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.
[67] Stefan Willmann,et al. Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling. , 2012, British journal of clinical pharmacology.
[68] C. Scriver,et al. The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.
[69] An-Ping Zeng,et al. The Connectivity Structure, Giant Strong Component and Centrality of Metabolic Networks , 2003, Bioinform..
[70] I. Goryanin,et al. Human metabolic network reconstruction and its impact on drug discovery and development. , 2008, Drug discovery today.
[71] D. Bergel. Geigy Scientific Tables , 1991 .
[72] C. Szabó,et al. Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol , 2006, Pharmacological Reviews.
[73] D. Kell,et al. High-throughput classification of yeast mutants for functional genomics using metabolic footprinting , 2003, Nature Biotechnology.
[74] M. Williams,et al. Purinergic and pyrimidinergic receptors as potential drug targets. , 2000, Biochemical pharmacology.
[75] J. Leonard,et al. Urea cycle disorders. , 2002, Seminars in neonatology : SN.
[76] E. Ruppin,et al. Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism , 2010, Molecular systems biology.
[77] L. James,et al. Mechanisms of acetaminophen-induced liver necrosis. , 2010, Handbook of experimental pharmacology.
[78] S. Willmann,et al. Risk to the Breast‐Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study , 2009, Clinical pharmacology and therapeutics.
[79] G. Murrell,et al. Clinical Pharmacokinetics of Allopurinol , 1986, Clinical pharmacokinetics.
[80] Ian David Lockhart Bogle,et al. Addressing the challenges of multiscale model management in systems biology , 2007, Comput. Chem. Eng..
[81] Walter Schmitt,et al. A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.
[82] Lars M. Blank,et al. Metabolic flux distributions: genetic information, computational predictions, and experimental validation , 2010, Applied Microbiology and Biotechnology.